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Abstract 
The zeta potential (ZP) of colloidal systems and nano-medicines, as well as their particle size exert a 
major effect on the various properties of nano-drug delivery systems. Not only the stability of dosage 
forms and their release rate are affected but also their circulation in the blood stream and absorption 
into body membranes are dramatically altered by ZP. In this paper the effect of ZP on the various 
properties of nano-medicines are reviewed. Furthermore, the ability of employing zeta potential to target 
drug delivery systems to, and drug release at specific sites of the body are discussed.  
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Nanoparticle surface is a very important 
consideration in targeting drug delivery. 
Conventional nanoparticles (without surface 
modification) and negatively charged particles 
can be rapidly opsonized and massively cleared 
by fixed macrophages of the reticuloendothelial 
system (RES) in the blood stream. Surface 
modification of nano-drug delivery systems is the 
most common strategy to controlling the 
opsonization process and thus sustain the 
systems for longer period in the blood stream. 
Suitable ZP can improve drug release profiles at 
specific sites as well as their stability in dosage 
forms. 
 
Effect of ZP on gene delivery systems The 
transfection efficiency of gene vector depends on 
the particle size and zeta potential [1]. A system 
that is simply negatively charged [2] or with a 
positive surface charge density might be 
desirable for loading DNA molecules [3]. 
Because many proteins, DNA and cell 
membrane surface are slightly anionic, so a 
positive ZP not only has benefits for enhanced 
DNA loading efficiency also might provide the 
effective accumulation in the target cells [4]. 
“Complexes” is the term in which particle 
formation is elicited by the tropism between DNA 
molecules and nanoparticles with positive 
surface charge [5]. 
 
The particle size and ζ-potential of vector/pDNA 
particles can influence the intracellular trafficking 
of particles and subsequent transfection 
efficiency. The particles are large at N/P ratios of 
2:1 to 4:1, corresponding to neutral or slightly 
positive zeta potentials, which demonstrates that 
particles possibly be gathered into a mass at the 
neutral condition. The ZP of binary complexes 
increases with increase in N/P ratios, and neutral 
or positive ZP were observed for N/P ratios of 2 
and greater. The transfection efficiency of gene 
vector depends on the particle size and zeta 
potential. Moreover, excess positive charge on 
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the complexes can cause the nonspecific binding 
and uptake by non targeted cells. Thus for 
complexes with targeting ligand, a weekly 
positively charged surface is preferable for the 
specific binding by receptor-mediated 
endocytosis. When complexes of N/P higher than 
the optimal value were added to the cultured 
cells, specific binding was inhibited in the 
presence of excess peptides. According to 
literature, arginine-rich peptides also show the 
same trend [6]. 
 
Previous studies aimed to develop an amphoteric 
hyaluronic acid (HA) derivative with 
polyethyleneimine (PEI) chains (HAP) for gene 
delivery to overcome the disadvantages of PEI 
as gene carrier including the cytotoxicity caused 
by excess of positive charge, non-special 
interaction and aggregation in the blood, and 
non-target gene delivery. At charge ratio of 1, 
where the complex could not form completely, 
the zeta potential was negative. But an 
interesting result was observed in that the zeta 
potential of HAP/DNA complex with higher 
molecular weight HA at certain charge ratio was 
positive, but not negative charge as expected. 
Moreover, electrochemical equilibrium process 
was observed in the course of determining ZP, 
which signified that the condensation process of 
DNA by HAP might be complicate [7]. 
 
Cationic nanoparticles of biodegradable 
polymers such as poly (lactide) (PLA) have been 
shown to be promising carrier systems for DNA 
and siRNA delivery. The cationic poly (d,l-lactide-
co-glycolide) (PLGA)–PEI, PLGA–chitosan and 
methoxy poly (ethylene glycol)–poly (lactide) 
PLGA/PEI and mPEG–PLA/PEI nanoparticles 
were prepared by a nanoprecipitation method. 
Surface modification of the nanoparticles into 
cationic surface was done to facilitate the loading 
of negatively charged dsRNA. The results 
showed that zeta potential of the nanoparticles 
significantly changed from negative to positive 
value after being modified by the 
polyethyleneimine (PEI) 25 kDa and chitosan. 
Since the surface charge of the nanoparticle 
delivery system was primarily determined by the 
amount of the amine group (NH2+) of PEI 25 
kDa and the chitosan coated on the surface of 
the nanoparticles, four groups of nanoparticles 
demonstrated different zeta potential indicating 
different charge potential of the nanoparticles. All 
of the four nanoparticles showed great dsRNA 
loading potential. This further confirmed the 
previous results that nanoparticles through 
polycations modification can absorb the negative 
charge nucleic acid and load it efficiently [8] and 
the charge interaction is firm enough to absorb 
the dsRNA at the surface of nanoparticles [9].  
Cationic nanoparticles combine the advantages 
of nanoparticles as a drug carrier and 
complexation ability with nucleic acid in acting as 
the gene carrier. With better biocompatibility and 
easy producing property, cationic nanoparticles 
have gained more and more attention in the gene 
delivery area. Unlike the delivery of plasmid 
DNA, transport of dsRNA is much easier since 
there is no need to deliver dsRNA into the cell 
nucleus (fig 1). Previous polymeric nanoparticles 
mediated gene delivery method tend to use 
double emulsion technique loading the 
therapeutic gene and was limited by the low 
encapsulation efficiency of the drug. Moreover, 
during the process of preparing nanoparticles 
through double emulsion technique, the contact 
of the dsRNA with a lot of organic solvent and 
the involvement of sonication procedure might 
damage or denature the dsRNA.  
 
Now, more and more researchers have 
employed cationic nanoparticles simply because 
it is an easy, safe and efficient way to carry 
therapeutic substances. Chitosan and 
polyethyleneimine (PEI) have both been used as 
cationic coating agents. The results demonstrate 
 that PEI 25 kDa is slightly better than the 
chitosan by showing higher gene transfection 
efficiency and higher loading efficiency of RNA. 
These results revealed that two factors affect the 
siRNA delivery efficacy of cationic nanoparticles 
in terms of higher DNA loading capacity than 
chitosan [10]. In addition, the zeta potentials of 
poly-siRNA/PEI complexes (1.54 ± 0.72 mV) 
were lower than that of mono-siRNA/PEI 
complexes (22.39 ± 0.53 mV), implying that most 
of the positively charged PEI chains in poly-
siRNA/PEI complexes were closely covered with 
the strongly anionic poly-siRNA. The most 
positively charged portion of PEI in mono-
siRNA/PEI complexes protruded from the 
complexes due to the weak electrostatic 
interaction with lower anionic charged mono-
siRNA. These results clearly reveal that poly-
siRNA produced more nano-sized and compact 
complexes than mono-siRNA via electrostatic 
interactions with PEI [11]. 
 
A good complexation of the negatively charged 
siRNA to the cationic dex-HEMA-co-TMAEMA 
nanogels is a prerequisite to successfully deliver 
siRNA across plasma membrane into cytosol. To 
evaluate this, nanogel samples were titrated with 
siRNA and the resultant zeta-potential of the 
siRNA-loaded nanogels was measured. Clearly, 
the loading of the nanogels with siRNA is 
reflected in the zeta-potential value as can be 
seen in the typical sigmoidal curves that are 
obtained; the lower positive surface charge of the 
DS 8.9 nanogels may result in a less efficient 
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cellular internalization. Fewer uptakes of DS 8.9 
nanogels by Huh-7 cells could indeed be 
confirmed by flow cytometry and is therefore one 
of the reasons which explain the lower gene 




Figure 1: Formation of lipid/DNA complexes [18] 
 
Effect of ZP on macrophage uptake 
 
Due to large surface area/volume ratio, 
nanoparticles tend to agglomerate and adsorb 
proteins. When bound to proteins, they may be 
quickly cleared by macrophages before they can 
reach target cells [13-14]. Hence, the 
aggregation of serum components and the 
thrombus formation can also result in embolism 
[3]. 
 
One possible approach to increase the 
circulation time of nanoparticles in blood stream 
is to modify particle surface and minimize or 
eliminate protein adsorption. The mechanism of 
protein adsorption has been attributed to 
electrostatic interaction. Electrostatic interaction 
of the nanoparticles can be controlled by 
variation in their surface charges, which can be 
determined by measuring the zeta potential of 
these particles. Nanoparticles having positive 
zeta potential displayed good protein adsorption 
[14], but in one investigation by creating a highly 
immunogenic (opsonizable) liposome containing 
negatively charged lipids, these formulations 
were rapidly removed from circulation by the 
reticuloendotelial system (RES) [15]. In general, 
however, negatively charged samples did not 
significantly adsorb protein. By varying the 
surface charges, one can vary the electrostatic 
interaction between the protein and the 
adsorbent for selective adsorption of a particular 
protein.  
 
Factors such as pH and solution electrolyte 
concentration have a considerable impact on the 
strengths and types of electrostatic charges on 
the adsorbent and thus can lead to different 
protein and surface interactions under different 
conditions [14]. The membrane of red blood cells 
(RBC) is also soft and composed of two-sub 
layers, the outer sub layer being negatively 
charged and the inner one being positively 
charged. According to some studies, the 
dominant factor to control the interaction 
between RBC and the synthetic polymer is the 
softness of the nanoparticle surface. It is 
considered that if the nanoparticles cover with 
synthetic polymers, they are not recognized as 
foreign materials by biological cells, if the 
polymer surfaces are soft and hydrophilic and in 
this way one can decrease the hemolytic 
potential [16]. 
 
It has been shown that NPs with high surface 
charge and large particle size are phagocytized 
more efficiently by murine macrophage. Slight 
particle size and surface charge differences and 
different cell lines had significant implications in 
the cellular uptake of NPs, and various 
mechanisms were involved in the uptake process 
(Fig 2). In vivo biodistribution suggested that NPs 
with slight negative charges and particle size of 
150 nm were tended to accumulate in tumor 
more efficiently. These results could serve as a 
guideline in the rational design of drug 
nanocarriers with maximized therapeutic efficacy 
and predictable in vivo properties, in which the 
control of particle size and surface charge was of 
significance. It has been shown that the surface 
charge of rhodamine B (RhB) labeled 
carboxymethyl chitosan grafted NPs (RhB-
CMCNP) and chitosan hydrochloride grafted NPs 
(RhB-CHNP) significantly affected their uptake 
by phagocytic cell. Macrophage uptake 
increased with the surface charge increasing 
(either positive or negative). This process could 
lead to increase in phagocytic uptake up to 1.3-
fold. When the absolute values of Zeta potential 
were similar, positively charged NPs showed a 
higher phagocytic uptake compared to negatively 
charged NPs irrespective of NPs composition. 
The cellular uptake of FITC-labeled protamine 
sulfate (FITC-PS) and camptothecin (CPT) 
showed the same tendency with their 
corresponding carriers and were slightly lower. 
Compared to those of the same composition and 
particle size, NPs carrying more surface charges 
exhibited smaller contact angle referring to the 
higher hydrophilicity, which might be attributed to 
the thicker hydrophilic shell [17]. 
 
It is known that scavenger receptors recognize 
anionic particles and facilitate uptake by the RES 
[18]. Negatively charged spherical particles can 
potentially bind to available cationic sites on the 
macrophage surface and be recognized by 
scavenger receptors while adsorption of proteins 
on their surface may alter their overall charge,  
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Figure 2: Biodistribution of RhB-CMCNP of varying ZP and size in different parts of the body [17]. Note: ■ = -15 
mv, 150 nm; ● = -25 mv, 150 nm; ∆ = -40 nm, 150 nm;     = -25 mv, 500 nm  
 
prevent such interaction and result in fewer 
uptakes. It must be noted, however, that the zeta 
potential of protein-bound spherical particles is 
only slightly negative at -6.1 mV, and hence in 
addition to the influence of surface charge, 
nanoparticle geometry has probably played a 
role in the cellular uptake and biodistribution of 
the nanoparticles [19]. 
 
PH-responsive liposomes containing synthetic 
glutamic acid-based zwitterionic lipids were 
developed by Obata et al. The zeta potential of 
liposomes containing 1,5-dihexadecyl N-
glutamyl-L-glutamate (L1) and/or 1,5-dihexadecyl 
N,N-diglutamyl-lysyl-L-glutamate (L2) was 
positive when the solution pH was below 4.6 or 
5.6, respectively, but negative at higher pH 
values. The pH-responsive liposomes showed 
improved fusogenic potential to an endosome-
mimicking anionic membrane at acidic pH. 
Fusion was clearly increased when the pH value 
was less than pH 5.5 or 6.0 for L1 or L2-
liposomes, respectively. Because the zeta 
potential of the L1 or L2-liposomes is positive 
under these pH conditions, the cationic 
liposomes should adhere to the negatively 
charged model membrane. Following the initial 
contact, membrane fusion then occurs by flip-flop 
movement of the lipids. Beside the fusion, the 
aggregation between the positively and 
negatively charged liposomes may occur [20]. 
 
Effect of ZP on immunogenicity of 
nanoparticles 
 
There are some investigations that showed that 
the surface charge of nanoparticles has an effect 
on the stimulation of the immune response. 
Previous literatures mentioned that while the 
negatively charged liposomes were 
immunostimulant the zwitteronic ones were not. 
Other authors have observed positive results 
using cationic liposomes or liposomes coated 
with cationic polymers such as protamine [21,22]. 
 
Effect of ZP on ocular drug delivery systems 
 
Positive ZP is important for ocular drug delivery 
since it can facilitate effective adhesion to the 
cornea epithelial surface, prolonging the drug 
release and enhancing the drug bioavalibility in 
the internal tissue of the eye due to the 
electrostatic interaction between the positively 
charged and the negatively charged present at 
the corneal surface [23]. Due to the highly 
positive charge that Chitosan Oligosaccharides 
(COS) carried, the adsorption of COS increased 
the density of positive electron cloud that 
resulted in the positive electricity of integral 
particle as well. This increment in surface charge 
was ascribed to the formation of complexes, with 
the coating mechanism involving hydrogen 
bonding between the polysaccharide and the 
glyceride head groups [24]. 
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Positive charge can facilitate an effective 
adhesion to the corneal surface and account for 
a strong interaction with the negatively charged 
mucosa of the conjunctiva and anionic mucin 
present in the tear film, prolonging the residence 
time of the formulation [25]. It was shown that 
nanoplexes had a positive zeta-potential that 
could favour the attachment of the nanosystems 
onto the ocular surface. The positively charged 
nanoplexes interact with negatively charged sites 
on the cornea and tight junctions, and result in 
loosening or opening of the tight junctions owing 
to alteration in the relative concentrations of 
specific ion species in the pore volume. Thus, 
intercellular and intracellular penetration rather 
than simple mucoadhesion could explain the 
prolonged residence time (up to 24 h) of the 
particles on the cornea [26]. 
 
Effect ZP on the uptake of NPs from gut 
 
Factors which govern the uptake of particles from 
the gut include: particle size, surface charge and 
physicochemical proprties of the particle [27]. 
Investigations showed that antigen loaded 
cationically charged particles could be beneficial 
for gut up take. Cationically modified antigen is 
taken up more vigorously compared with non 
modified form [28]. The positively charged drug 
loaded nano particles are expected to interact 
with negatively charged sialic acid and fucose 
residues of mucin in the intestine by electrostatic 
interactions [29]. 
 
Effect of ZP on respiratory nano-drug delivery 
 
Although poly(styrene) and poly(D, L-lactide-co-
glycolide) nanoparticles revealed a dose-
dependent influence on biophysics of pulmonary 
surfactant, positively-charged nanoparticles 
made from poly(butyl methacrylate-co-(2-
dimethylaminoethyl) methacrylate-co-methyl 
methacrylate) showed no effect. This behavior is 
attributed to differences in ZP and surface 
hydrophobicity, which in turn involves an altered 
adsorption pattern of the positively charged 
surfactant proteins to the nanoparticles. It was 
shown that adsorption of cytochrome C 
depended on both nanoparticle surface 
properties, i.e., surface charge and surface 
hydrophobicity [30]. Although maximal protein 
adsorption is usually observed with hydrophobic 
surfaces, a diverse effect was obtained in the 
case of the highly negatively-charged polymeric 
nanoparticles with hydrophilic surface (PLGA-
NPs). Increasing surface hydrophilicity and 
keeping surface charge density almost constant 
led to a similar adsorption of cytochrome C to 
nanoparticle surfaces. Normally, more 
hydrophilic nanoparticle surfaces are known to 
decrease protein adsorption, but the high 
negative surface charge-density of PLGA-NPs 
facilitated electrostatic interactions with the 
positively charged cytochrome C. Interestingly, it 
was observed that cytochrome C was able to 
overcome repulsive coloumbic forces and adsorb 
onto similar charged surfaces like Eudragit E100 
(EU-NPs). Therefore, it is evident that a fine 
balance between electrostatic and hydrophobic 
interactions governs the adsorption process of 
cytochrome C to nanoparticles [30]. 
It appears that the positive surface charge of 
stearylamine-PEG-PLA NPs resulted in 
increased pulmonary side effects along with a 
transient systemic toxicity mainly on white blood 
cells. Therefore, these cationic NPs are not 
recommended for repeated local pulmonary 
instillation. The overall results suggest that 
anionic PEG-PLA NPs can be considered as 
drug carriers for local delivery following repeated 
instillations to the lungs and merit further 
investigation [31]. 
 
 Effect of ZP on pharmacokinetics 
 
Particle size and surface charge of nano particles 
regulate the biodistribution and pharmacokinetic 
properties of the nanoparticles in the body. 
Altering parameters such as size, conformation 
and charge can have profound effect on how a 
nanoparticle acts with and behave in biological 
environment [32]. Various investigations showed 
that negatively charged nanoemulsions are 
cleared faster as well as higher 
reticuloendothelal uptake than neutral or 
positively charged nanoemulsions [32]. Other 
investigations showed that increasing the 
liposome diameter and adding appositive charge 
on the liposomes showed higher liposomes 
clearance from injection site compared with 
smaller sized and neutral liposomes, 
respectively, after 2 h [16,33]. 
The protein adsorption and cellular uptake of 
cerium oxide nanoparticles with positive and/or 
negative surface charge was studied in previous 
literatures. The comparison of BSA adsorption 
and nanoparticles ZP clearly showed that 
positive ZP for nanoceria particles favours the 
protein adsorption. The negatively charged 
protein did not significantly adsorb protein [34].  
 
EFFECT OF ZP ON THE PHARMACEUTICAL 
PROPERTIES OF NANO-DELIVERY SYSTEMS 
 
Effect of ZP on controlled drug release: 
 
The release behaviour of drugs in vitro can be 
controlled by regulating the dissolubility, pH and 
Zeta potential of the material [23]. For example, 
chitosan showed that it could interact with 
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negatively charged (acidic) drugs when 
incorporated into films and this might affect drug 
release characteristics as well as the 
physicochemical property of the drug and 
polymer [35, 36]. As another example, direct 
interaction between doxorubicin (DOX) and poly 
(ethylene oxide)-b-poly (methacrylic acid) 
(PEOb-PMA) block copolymer results in the 
formation of complexes. The hydrophobic 
interactions between the anthracycline residues 
of DOX provide for additional stabilization of the 
complex. Alternatively, at lower loading, there are 
more negative charged groups available in the 
micelles and DOX can be better retained by the 
electrostatic interactions. Furthermore, faster 
release of DOX was also observed for the DOX-
loaded micelles with high density of cross-links 
(70%), which may have more peripheral drug 
localization and hence faster release [36]. In 
another study, layer by layer (LbL) coating 
technique which produces nanoparticle drug 
delivery systems with improved biocompatibility 
and sustained or targeted release of drug was 
used based on sequential electrostatic layer-by-
layer (LbL) adsorption of oppositely charged 
polyelectrolytes (PEs) on a charged substrate 
produces ultra-thin PE multilayers with controlled 
properties [37]. 
 
 Effect of ZP on drug loading efficiency 
 
The surface charge of the particles and binding 
type between the drug and nanoparticles are the 
important parameters that determine the rate of 
desorption of the drug in the nanoparticles and 
drug loading efficiency. The zeta potential also 
can be used to determine whether a charged 
active material is encapsulated within the center 
of the nanoparticle or on the surface [38-39]. 
Cationic charge on liposomes has also been 
shown to reduce their circulating half life in blood 
and to affect their biodistribution between the 
tumor microvasculature and interstitium without 
impacting overall tumor uptake [40]. Electrostatic 
interaction between charged block copolymers 
and oppositely charged macromolecules has 
allowed the formation of core–shell 
nanoparticles, which are termed “polyion 
complex micelles” (PIC) and in this way loading 
efficiency will be improved [41,42]. By 
measurement of the ZP of the drug or substrate, 
one can determine if the drug is shielded or not 
by the nano particles because if the drug is 
shielded by the nanoparticles ZP will be close to 
nanoparticle ZP or zero ZP [43]. As an example, 
the adsorption of tetanus toxoid as a cationic 
antigen at the negatively charged surface of 
blank nanoparticles composed of sulfobutyl-
poly(vinyl alcohol)-g-poly(lactic-co-glycolic acid) 
copolymers with a core–corona structure showed 
that the nanoparticle surface properties dictated 
the adsorption efficiency of tetanus toxoid onto 
the nanoparticles, and as expected, the maximal 
loading rate was achieved at the highest degrees 
of sulfobutyl substitution, which implies that the 
nature of the tetanus toxoid–nanoparticle 
interactions was primarily electrostatic [44]. 
 
The effect of drug loading on ZP of liposomes 
was studied through an isothermal titration 
colorimetry method. The results showed that the 
addition of drugs (alprenolol, labetalol, 
propranolol and tetracaien) have no significant 
effect on the liposome ZP and the ZP remained 
practically constant. It was discussed that the 
most probable explanation for the phenomenon 
is that because of high salt concentration in the 
medium, the degree of ion binding of sodium ions 
to the liposome membrane is quite high and they 
are just replaced by the added drug molecules. 
Thus the changes in the surface charge of 
liposmes and hence their effect on the ZP 
remains minimal during the titration [45]. 
Nanogels with lower ZP showed higher siRNA 
amounts [12]. Increasing flurbiprofen loading led 
to higher ZP, most likely due to the location of 
the drug molecules onto the NLC surface 
contributing to their negative charge. The 
analysis showed that the drug is encapsulated in 
the polymer matrix rather than physically 
adsorbed on the nanoparticle surface, and the 
drug also maintains its crystalline nature inside 
the matrix. In addition, the entrapment efficiency 
of calcitonin was observed to increase by 
increasing the negative zeta potential of the 
particles, which reflects an ionic interaction 
between the positively charged peptide drug and 
the NPs [45]. 
 
 Effect of ZP on stability of nanoparticle 
dispersion 
 
ZP is an indicator of the stability of NP 
suspensions. A higher electric charge on the 
surface of the NPs will prevent aggregation of the 
NPs in buffer solution because of the strong 
repellent forces among particles [46-47]. Tween 
80 also provides a steric stability for maintaining 
the stability of single layer nanoemultion (SLN) 
[48-49]. As a rule of thumb, absolute ZP values 
above 30 mV provide good stability [50-51] and 
above 60 mV excellent stability. About 20 mV 
provide only short term stability, values in the 
range -5 mV to +5 mV indicate fast aggregation. 
This is valid for low molecular weight surfactants 
and pure electric stabilization, but not for higher 
or large molecular weight stabilizers, which act 
mainly by steric stabilisation. In this case ZP 
values of only 20 mV or much lower can provide 
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sufficient stabilization. It has to be kept in mind 
that adsorbed layers of polymers/large molecules 
shift the plane of shear to a farer distance from 
the particle surface. This leads to a reduction of 
the measured zeta potential. That means even in 
case of highly charged particle surfaces, a 
relatively low ZP will be measured. Despite the 
low ZP, the suspensions are stable [52]. 
 
In the case of suspensions, re-suspension of 
particles from powder is extremely complex. 
Several factors can influence this process, 
particularly size, form, electrostatic particle 
charge and ambient humidity [21]. The stability of 
emulsion and colloids, according to DLVO 
electrostatic theory, is a balance between the 
attractive van der Waals’ forces and the electrical 
repulsion because of the net surface charge. If 
the zeta potential falls below a certain level, the 
emulsion droplets or colloids will aggregate as a 
result of the attractive forces. Conversely, a high 
zeta potential (either positive or negative), 
typically more than 30 mV, maintains a stable 
system [29-30]. 
 
Colloidal stability in biological environments can 
be a challenging issue in clinical application of 
any nanoparticle-based constructs due to the 
large surface area to volume aspect ratio of 
nanoscale materials. Charged cationic 
nanoparticles, in particular, often display poor 
stability in cell culture conditions, as they tend to 
adsorb proteins from the biological environment 
through electrostatic interaction, causing fouling 
or precipitation. 
 
Zeta potential is an important physicochemical 
parameter that influences the stability of 
nanosuspensions. Extremely positive or negative 
zeta potential values cause larger repulsive 
forces, whereas repulsion between particles with 
similar electric charge prevents aggregation of 
the particles and thus ensures easy redispersion 
[34,35]. In the case of a combined electrostatic 
and steric stabilization, a minimum zeta potential 
of ± 20 mV is desirable. 
 
Application of ZP in mucoadhesive systems 
 
Positive zp may give rise the strong electrostatic 
interaction with mucus or negatively charged 
mucosal surface. So we can use positively 
charged nano particles such as chitosan coated 
nano particles for mucoadhesive drug delivery 
systems as their positively charged surface can 
be in favour of adhesion to the cell mucosa which 
are normally negatively charged [53]. 
 
COMPARISION OF POSITIVE AND NEGATIVE 
ZP IN NANO-DRUG DELIVERY SYSTEMS 
 
As we said in other parts, positively charged 
nanoparticles has some advantages in targeted 
drug delivery because of negatively cell surface 
but investigation on liposomes showed that both 
positive and negative charges are known to 
enhance the delivery of liposomes to cells 
through adsorptive endocytosis and the half-life 
clearance of liposomes from the blood can range 
from minute to hours and the distribution to 
organs can be controlled in part by altering the 
physical properties such as size, charge and 
fluidity. However, positively charged lipids are not 
approved by FDA for clinical use [2]. Because 
liposomes or nanoparticles ZP is an important 
factor for their cytotoxicity and in some cases 
cationic charge is claimed to enhance cytotoxicity 
[54-56]. Positive charge posses a membrane 
destabilizing and concomitantly destructive effect 
resulting from an interaction of positive charge 
and negative charge of membrane [57]. The 
main factors influencing cytotoxicity of positively 
charged nanoparticles are said to be: 1) 
molecular weight, 2) charge density and type of 
cationic functionality, 3) strudture and sequence, 
4) conformational flexibility. Structure toxicity 
relationship could be visualized in a plot of 
logarithemic IC50 values versus the molecular 
weight/charge ratio. A linear relationship can be 
observed [55]. Investigations on dendrimers 
showed that positively charged amine and 
guanidine groups, demonstrated dose- and time-
dependent hemolytic activity [54]. 
 
In the case of negatively charged nanoparticles, 
investigations of liposomes showed that 
negatively charged liposomes does not show 
good accumulation in the lymph nodes (1/2 % of 
the injected dose) in comparision with positively 
charged (up to 3/6% of the injected dose), and 
also negatively ones showed lower drug 
entrapment [58], and some degree of drug 
release during storage [3], but the negatively 
charged nano particles are cleared more slowly 
from the blood compared to positively charged 
nanoparticles following IV administration to rat, 
and remained  in blood stream for longer time 
[59]. 
 
Isoelectric point values of positively charged 
nanoparticles above 10 involved very rapid 
clearance from the blood stream [60]. Also, 
negatively charged had lower cytotoxicity 
compared with positively one and approved by 
FDA. As one can see, both positive and negative 
zeta potential have their benefits. Therefore, the 
surface charge density of nano particles should 
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be optimized for minimal toxicity and effective 
intracellular delivery of encapsulated drug. 
 
 CONCLUDING REMARK 
 
Charge modification of nano-systems offer an 
opportunity for prolonging the blood circulation 
time of drugs, enhancing the possibility of its 
interaction with target cells of interest, and 
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